These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 18157576

  • 1. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
    Harrison LE, Bryan M, Pliner L, Saunders T.
    Ann Surg Oncol; 2008 May; 15(5):1407-13. PubMed ID: 18157576
    [Abstract] [Full Text] [Related]

  • 2. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H.
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [Abstract] [Full Text] [Related]

  • 3. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.
    Ann Surg Oncol; 2007 Oct; 14(10):2790-7. PubMed ID: 17661150
    [Abstract] [Full Text] [Related]

  • 4. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
    Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y.
    Ann Surg Oncol; 2009 Feb; 16(2):345-51. PubMed ID: 19018599
    [Abstract] [Full Text] [Related]

  • 5. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [Abstract] [Full Text] [Related]

  • 6. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M.
    In Vivo; 2008 Feb; 22(1):153-7. PubMed ID: 18396799
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA.
    J Clin Oncol; 2003 Oct 15; 21(20):3737-43. PubMed ID: 14551293
    [Abstract] [Full Text] [Related]

  • 8. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M.
    In Vivo; 2010 Oct 15; 24(1):79-84. PubMed ID: 20133981
    [Abstract] [Full Text] [Related]

  • 9. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M.
    Eur J Surg Oncol; 2010 Nov 15; 36(11):1047-53. PubMed ID: 20832234
    [Abstract] [Full Text] [Related]

  • 10. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.
    Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA.
    Ann Surg Oncol; 2004 Apr 15; 11(4):375-9. PubMed ID: 15070596
    [Abstract] [Full Text] [Related]

  • 11. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
    Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E.
    J Surg Oncol; 2012 Aug 01; 106(2):197-203. PubMed ID: 22331814
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.
    Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.
    Drug Metab Dispos; 2012 Dec 01; 40(12):2365-73. PubMed ID: 22972909
    [Abstract] [Full Text] [Related]

  • 13. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
    Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.
    Cancer; 2008 Jul 15; 113(2):315-25. PubMed ID: 18473354
    [Abstract] [Full Text] [Related]

  • 14. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, North-Eastern German Society of Gynecological Oncology.
    Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):585-91. PubMed ID: 19156414
    [Abstract] [Full Text] [Related]

  • 15. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
    Vaira M, Scuderi S, Costamagna D, Barone R, Aghemo B, Mioli PR, De Simone M.
    Minerva Chir; 2002 Oct 15; 57(5):597-605. PubMed ID: 12370661
    [Abstract] [Full Text] [Related]

  • 16. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
    Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK.
    Ann Surg Oncol; 2007 Aug 15; 14(8):2309-18. PubMed ID: 17541691
    [Abstract] [Full Text] [Related]

  • 17. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Chua TC, Morris DL, Esquivel J.
    Ann Surg Oncol; 2010 May 15; 17(5):1330-6. PubMed ID: 20033321
    [Abstract] [Full Text] [Related]

  • 18. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J.
    Ann Surg Oncol; 2012 Jul 15; 19(7):2186-94. PubMed ID: 22395983
    [Abstract] [Full Text] [Related]

  • 19. A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC.
    Harrison LE, Tiesi G, Razavi R, Wang CC.
    Ann Surg Oncol; 2013 Jun 15; 20(6):1843-50. PubMed ID: 23354567
    [Abstract] [Full Text] [Related]

  • 20. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
    Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M.
    Cancer; 2002 Jan 15; 94(2):492-9. PubMed ID: 11900234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.